Acta Scientific Gastrointestinal Disorders (ISSN: 2582-1091)

Volume 7 Issue 8 August 2024

Research Article

Machine Learning Insights: Enhancing Hepatitis C Screening Efforts for Improved Patient Outcomes

Muhammad Umar[1]*, Zeib Jahangir[2], Qurat-ul-Ain[3], Fiza Saeed[4], Sheena Shiwlani[5] and Ashish Shiwlani[6]

[1]Department of Computer Science, Illinois Institute of Technology, USA

[2]Department of Computer Science,William Jessup University San Jose, California, USA

[3]Gastroenterology, Buch International Hospital Buch Villas, Multan

[4]Department of Biomedical, Engineering University of Texas Arlington, Texas, USA

[5]Biorepository & Pathology CoRE, Mount Sinai Hospital, New York City, New York, USA

[6]College of Computing, Illinois Institute of Technology Chicago, Chicago, USA

***Corresponding Author:** Muhammad Umar, Department of Computer Science, Illinois Institute of Technology, USA.

DOI: 10.31080/ASGIS.2024.07.0656

Received: June 06, 2024

Published: July 31, 2024

Abstract

Hepatitis infection is still a major global health concern, requiring effective measures to screen and manage it so that its impacts are reduced specifically hepatitis C. The past few years have seen the coming up of using AI and ML technologies together thus promising better ways of screening for hepatitis C and caring for the patients thus making everything better. In this article, some of the most real-life benefits of using Artificial Intelligence (AI) and Machine Learning (ML) for diagnosing hepatitis C are highlighted. This paper will first analyze the diagnostic methods for hepatitis C. It is important to note that the significance of artificial intelligence in examining radiological findings using imaging techniques like CT scans, MRI scans, and Ultrasound results cannot be overemphasized. The article discusses the ethics and rules related to AI use in healthcare, such as hepatitis C testing. If patient data is mishandled, trust deteriorates, making it hard for any computer system to access or control it. Such breaches of privacy during AI-assisted screenings could turn people away from these technologies and towards less precise traditional methods. Despite these challenges, folks think there's a big chance to identify and avoid hepatitis C using AI and Machine Learning (ML). These tools could boost screenings, predict outbreaks, and improve treatments. This changes how we care for hepatitis C patients. By leveraging large datasets and state-of-the-art algorithms, AI-supported screening systems can totally change the way diseases are detected as well as its effects on public health. In conclusion, the review highlights the significant impact of AI and ML technologies in enhancing hepatitis C screening, diagnosis, and management. Using AI algorithms can enable healthcare systems to improve detection rates at an early stage, come up with optimized therapeutic strategies thus easing burden of hepatitis C on both individuals and healthcare systems.

Keywords: Hepatitis C Virus (HCV); Artificial Intelligence (AI); Machine Learning (ML); AI Algorithms; HCV Staging; Public Health Impact.

Introduction

In 2024, the hepatitis C epidemic continued to be a serious global public health concern. Hepatitis C exposure is thought to have affected 4.1 million persons in the US [1]. Of persons infected with HCV, 55 to 85% get chronic liver disease, and 15 to 30% develop cirrhosis [2]. The incidence of hepatitis C persisted even after improvements in treatment and prevention occurred. This was especially true for some high-risk groups, including drug injectors, those who had previously received blood transfusions prior to the introduction of blood screening programs, and residents of areas with poor access to medical facilities. Though the screening initiatives are commendable, they often identified a significant number of undiagnosed people affirming the necessity of active testing schemes as well as improving consciousness on the problem. Moreover, there are disparities between regions on HCV burden whereby some areas are characterized by high infection levels mainly due to issues around intravenous drug use prevalence and disparities within the health care system. Both urban and rural regions recruited 4323 and 9321 individuals, respectively. Anti-HCV frequencies were 0.56% and 0.49% in both locations, respectively, while 0.1% of patients had positive HCV RNA tests. Fifty-two anti-HCV positive patients and eight cases of HCV-RNA positive patients were unaware that they were infected (a total of 262 tests are needed to find one unknown anti-HCV positive patient). Out of the three thousand patients, twenty-two percent had elevated blood ALT or at least one of the three risk factors: immigration, blood transfusions, and IV drug misuse. By restricting HCV screening to individuals with risk factors, anti-HCV and HCV-RNA were discovered in 52% and 75% of all undiagnosed cases, respectively [3]. It was essential to have such programs to identify cases early and connect patients with appropriate medical care since those programs were directed at high-risk populations. Nevertheless, there were problems when reaching out to certain underprivileged areas in addition to keeping track of care for those with hepatitis. One has to give hospital services and medications at fair prices so as to minimize the burden and prevalence of hepatitis C through increased screening uptake and access to reasonably priced treatment options. Improvements in HCV treatment techniques have also presented intriguing paths to lower disease morbidity and mortality, such as the very successful direct-acting antiviral (DAA) medications. Owing to incomplete prevalence data, a statistical model created by the University of Albany calculated that 189,000 people in New York State are HCV positive [4]. Regretfully, there is insufficient information about the prevalence of HCV exposure in nearby towns, which begs the question of whether efficient screening programs are in existence. Deployment of machine learning (ML) and artificial intelligence (AI) in disease identification marked a significant advancement in the medical sector. AI employs enormous databases and sophisticated algorithms to detect illnesses that previously were inconceivable due to their speed and precision among doctors. AI-driven screening systems enable early diagnosis and treatment, as well as better patient outcomes, by taking a proactive approach to healthcare. Proactive measures include, for example, using patient data to predict the likelihood of heart disease or using medical images to identify early cancer indications. The purpose of artificial intelligence (AI), a relatively new science, is to expand, enhance, and simulate human intelligence through research and development of theory, method, and application [5]. In the medical domain, artificial intelligence (AI) is typically classified into two categories: deep learning, which is based on neural network architecture, and classical AI, which includes machine learning [6]. When compared to Traditional AI, deep learning may use an image directly into the learning process without the requirement for manual feature extraction. Additionally, deep learning can iterate and learn from past errors, but in order to completely demonstrate its precise and resilient efficiency, more huge data and result analysis are required [7]. In particular, a literature review of the literature has been conducted from the following perspectives

- ***RQ1:*** What are the methods used for hepatitis C screening?
- ***RQ2:*** How might artificial intelligence and machine learning be applied to enhance hepatitis C detection and prevention efforts?
- ***RQ3:*** What role may AI and ML play in HCV staging?
- ***RQ4:*** How can artificial intelligence forecast whether treatment plans would fail?
- ***RQ5:*** What are the potential drawbacks and restrictions of AI and ML in the screening and prediction of hepatitis C?

Methodology

Research scope definition

The focus of the literature review was to define the scope of the application of machine learning (ML) and artificial intelligence (AI) in screening for diagnosing or managing hepatitis C. Target areas were machine learning algorithms, predictive modeling techniques, disease staging issues and ethical considerations among other things including integration into clinical processes.

Literature search strategy

We examined several academic databases, including PubMed, Scopus and IEEE Xplore, where appropriate terms like “hepatitis C,” “machine learning,” “artificial intelligence,” “screening” were used to conduct an organized scanning process for this study. The review focused on including most recent developments considering research literature published by authors working within ten years of their time who are members among other things peer reviewed journals.

Data extraction and synthesis

Data from selected articles were extracted and synthesized to identify common themes, trends, challenges, and opportunities in the application of ML in hepatitis C management. Key findings related to AI-driven approaches, predictive modeling, stages and disease severity estimation, treatment plans, and the drawbacks of AI were systematically reviewed and analyzed.

Analysis and interpretation

Meaning insights and conclusions were crafted from the data that had been extracted to explain what role ML plays in boosting operations aimed at screening hepatitis C. The findings were amalgamated by the review to give a summary that covers all angles of AI applications in hepatetis C management today and at the same time pointing out possible implications on clinical practice.

Manuscript writing

The findings, analysis, and recommendations from the literature review were structured into a coherent narrative to present a comprehensive overview of the role of ML in hepatitis C screening and management. The methodology, results, and implications of AI applications in hepatitis C were organized to provide valuable insights for researchers, healthcare professionals, and policymakers in the field.

Research Findings

Methods of Screening of Hepatitis C

To check for hepatitis C, a person's blood antibody to HCV (anti-HCV) level is employed. A positive test (antibody detection) does not indicate the presence of hepatitis C; rather, it only indicates prior exposure to the virus. The screening test that is now in use has 100% specificity and a sensitivity of at least 97% [8]. A 97% sensitivity means that 97% of people who have been exposed will be detected by the screening test. With a 100% specificity, all those who did not have hepatitis C had negative screening test results and no false-positive findings.

Hepatitis C screening is hampered by a number of factors, such as poor health insurance coverage, restricted access to healthcare, people's fading memory of past risky behavior. Furthermore, in a poll of community-based physicians, almost 42 percent of primary care physicians said they were not familiar with the CDC guidelines. [9]. Artificial intelligence (AI) can assist in the analysis of radiological data from magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound, all of which are frequently utilized in the diagnosis and distinction of liver pathology [10]. Neural networks can distinguish between cirrhotic liver and HCC with an accuracy of 94.5% when used in ultrasound scans. Additionally, distinctions between focal nodular hyperplasia (FNH) and atypical HCC have been documented on contrast-enhanced US, with a classification accuracy of 94.4% when compared to pathology report analysis (biopsy or resection) and subsequent clinical follow-up [11].

Based on US medical claims and prescription data, a retrospective, case-control cohort analysis revealed that predictive models were created to find undiagnosed HCV individuals. Descriptive data indicates that individuals diagnosed with HCV had significant interactions with the healthcare system in the four years prior to the diagnosis. First of all, this offers some indication that these patients might receive a diagnosis sooner in their journey, which would improve the results as expected. Secondly, even if a lot of these pre-diagnosis interactions are linked to known risk factors, the low specificity of the risk variables makes it doubtful that a straightforward rules-based risk screening program will be very successful. For example, only 26 percent of individuals with an HCV diagnosis had IV drug usage. The objective of the study was to increase the effectiveness of Hepatitis C Virus (HCV) screening programs by employing AI and machine learning strategies. We explored four different types of classifiers namely: logistic regression, random forest, gradient boosting tree-based model (GBT), stacked ensemble based on data pertaining to patients. Stacked ensemble posted the best performance in terms of recall as well as precision rates making it outshine other models during this experiment. Among the key risk factors were IV drug use, age, prior symptoms of HCV illness and pain relief treatments for arthritis; this was revealed by the algorithm. The proposed AI techniques would help increase the accuracy of HCV screening tests. However, some limitations emerged such as the need for external confirmation and probable biases in billing records.

The potential future directions and applications of AI/ML in improving hepatitis C detection and prevention efforts

A study was made under the title of "Hepatitis C Virus prediction based on machine learning framework: a real-world case study in Egypt". Focuses on utilizing machine learning (ML) approaches to predict and classify Hepatitis C Virus (HCV) among healthcare workers in Egypt [25]. The study gathered true-to-life data from the National Liver Institute in Menoufiya University in Egypt for 859 patients having twelve disparate attributes. Induction algorithms and classifiers using machine learning techniques like random forest (RF), Naïve Bayes,K-nearest neighbor and logistic regression were utilized in evaluating the model. The research examines two scenarios: in one, features were selected using stepwise approach forward selection (SAFS); in the other, no feature selection was carried out [12]. The findings showed that, in comparison to when feature selection was not used, the suggested framework had better accuracy following SFS selection. The random forest classifier is used to minimize the training time down to 0.54 seconds while achieving 94.06% accuracy. The rating of classification was raised to 94.88% by changing the hyperparameters of RF classifier in order to make use only of four attributes. The selected features have been shown in table 1 through Sequential Forward Selection (SFS) technique that was implemented together with different classifiers

- **SFS + Naïve Bayes (NB):** Naïve Bayes is based on Bayes' hypothesis and built with the assumption of feature independence, thus, a probabilistic classifier. It finds applications in situations like illness screening during medical diagnoses, among other classification jobs [41,42].
- **SFS + Random Forest (RF):** A number of Decision Trees are constructed by ensemble learning techniques during training for Random Forest, which afterwards generates a prediction that is the class mode. Due to its acclaimed accuracy and precision in classification tasks, it is most suitable for diseases screening and prognosis [43].

Paper	Algorithms	Measured variables	Dataset	Main findings	Outcome measured
[28]	Support Vector Machines, Bayesian Networks,	Not mentioned	EHRs	Diagnosis and therapy of hepatic disorders is increasingly evident, and integration of AI with conventional diagnostic methods enhances diagnostic performance.	progression of disease, complications, mortality, prediction of fatty liver disease, distinguishing benign tumors from hepatocellular malignancy, predicting diagnosis and consequences of liver cirrhosis, hepatocellular carcinoma (HCC), and nonalcoholic fatty liver disease
[29]	PyRadiomics, Boruta, PLR, GBM	blood AFP levels, pathological diagnosis datasets	CT/MRI images, blood AFP data, and pathological diagnosis data of 171 patients from Zhejiang Provincial People's Hospital	Prediction models for HCC diagnosis and ES grade prediction	HCC diagnosis and Edmondson-Steiner (ES) grade prediction
[26]	Regularized regression (RR), Logistic regression (LR), Random Forest (RF), Decision tree (DT), Extreme gradient boosting (XG Boost)	Total bilirubin, GGT, direct bilirubin, hemoglobin, age, platelet, ALP, AST, creatinine, ALT, cholesterol, albumin, urea nitrogen, white blood cells, gender, cholinesterase, urine protein, red blood cells	The dataset used in the study consists of 525 patients suspected to have liver disease at The Affiliated Hospital of Zhengzhou University, including various parameters related to liver disease.	Early detection and classification of liver diseases, particularly in low-income regions.	Classification of liver diseases based on significant risk factors or clinical parameters, including accuracy, recall, F1-score, and AUC
[37]	CLIF-SOFA	Not mentioned	The dataset used in the study includes demographic data, baseline laboratory parameters, duration of hospitalization, study protocol, and ethical approval.	CLIF-SOFA scores were identified as independent predictors of mortality	Mortality of cirrhotic patients hospitalized with hepatic encephalopathy
[33]	Decision trees, random forests, SVMs, k-NN classifiers, AdaBoost, and Gradient Boost	Accuracy and precision percentages	hepatocellular carcinoma dataset from the UCI machine learning repository	Hepatocellular carcinoma detection, with gradient boost achieving the highest accuracy and precision.	Performance of machine learning techniques using gradient boost with 84% accuracy and 93% precision.
[27]	Classification, regression, and artificial neural networks	Medical data parameters	The dataset used in the study likely consists of medical data related to HCC patients, including clinical trials, laboratory studies, tumor grading, and imaging studies.	Prediction of Hepatocellular Carcinoma (HCC) by reviewing various previous studies on the topic.	Prediction of Hepatocellular Carcinoma (HCC) using machine learning techniques like classification, regression, and artificial neural networks
[30]	Recurrent Neural Networks (RNNs)	AFP, ALP, ALT, AST, GGT, among others	The dataset used in the study consists of various HCC risk scores and biomarkers that were externally validated in independent patient cohorts, including the Toronto HCC risk index (THRI), the map score, and HCC-risk-predictive algorithms for specific clinical contexts.	Predicting HCC risk with emerging predisposing conditions	Not mentioned

[34]	Multilayer Perceptron	Serum levels of α-fetoprotein (AFP), AFP-L3, des-γ-carboxy prothrombin (DCP), and Golgi protein 73 (GP73)	The dataset used in the study includes 347 patients with HCC and LC, divided into advanced HCC, early-stage HCC, and LC groups, with demographic data and serum marker levels compared between the groups.	Diagnostic potential of four serum biomarkers for HCC and developed models with high sensitivity for HCC diagnosis.	Development of HCC diagnostic models using ANN and four serum tumor biomarkers (AFP, AFP-L3, GP73, and DCP) to distinguish early-stage HCC from LC patients
[35]	IPM, CU-HCC, GAG-HCC, NGM-HCC, REACH-B, Page-B, LSM-HCC, mREACH-B	Old age, male gender, initial serum AFP level, platelet count, serum albumin, severe liver parenchymal echogenic pattern, heavy alcohol consumption, sex, age, serum levels of alanine aminotransferase, HBeAg status, levels of HBV DNA, liver stiffness values, clinical and demographic data, smoking status, alkaline phosphatase level, and Epidermal Growth Factor Gene genotype	The datasets used in the study are from Korean, Chinese, Taiwanese, and American patients with chronic hepatitis B.	Individualized prediction models for HCC development in CHB patients	risk for HCC development in CHB patients as assessed by various prediction models
[36]	Artificial Neural Netwroks	α-fetoprotein (AFP), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), sialic acid (SA), calcium (Ca)	The dataset used in the study includes 140 serum samples categorized into malignant, benign, and normal samples, with measurements of five tumor markers: α-fetoprotein (AFP), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), sialic acid (SA), and calcium (Ca)	Developed a computer-aided diagnostic scheme using an artificial neural network combined with tumor markers for the diagnosis of hepatic carcinoma	Diagnostic accuracy of the artificial neural network (ANN) in differentiating hepatic carcinoma (HCC) from benign or normal samples (95.5%)
[32]	Hepascore Algorithm	Serum levels of hyaluronic acid, GGT, A2M, and total bilirubin; Hepascore values; Severity of fibrosis estimated by Hepascore; Severity of fibrosis detrrermined by liver biopsy	The dataset used in the study includes 80 patients with chronic Hepatitis C, their demographic information, liver biopsy results for fibrosis staging, serum biomarker levels, and Hepascore calculations.	Hepascore is effective in diagnosing the level of liver fibrosis, especially cirrhosis, showing reasonable sensitivity, specificity, NPV, and PPV. It can be used as a primary screening tool to assess the necessity for liver biopsy.	Effectiveness of Hepascore in predicting the level of liver fibrosis
[38]	Artificial Neural Networks (ANN)	Biochemical indexes	The dataset used in the study includes basic information and laboratory data from patients, biochemical tests for specific diseases, multivariate variables from biochemical indexes, output variables from diagnosis, and data from 60 patients diagnosed with abnormal liver function.	Utilized Artificial Neural Networks to analyze biochemical tests for diagnosing liver diseases	Positive predictive value of biochemical indexes for hepatitis, hepatic carcinoma, cirrhosis, and cholecystolithiasis
[31]	Individual Prediction Model (IPM)	Risk factors of 4,339 Korean patients	4,339 Korean patients with chronic B viral liver disease	An individual prediction model (IPM) was developed based on the risk factors of Korztients to establish a self-exploited screening program for HCC.	Early detection of hepatocellular carcinoma (HCC)

Table1: The summarized literature review for the screening of Hepatitis C using different machine learning and artificial intelligence algorithms.

- **SFS + K-nearest Neighbor (KNN):** For new cases, the K-Nearest Neighbor algorithm is simple and stores all available scenarios and utilizes a similarity measure (such as distance functions) to place new cases in appropriate categories. In disease prediction and screening tasks in health care, KNN is common for pattern recognition process [44,45].
- **SFS + Logistic Regression (LR):** Logistic Regression is a statistical model that is often used for binary classification in medical research. In other words, it helps to establish a connection between the outcome of a dependent variable and/or predictor variables designed by researchers. This model is capable of predicting the probability of a variable falling within a particular category [46,47].

Staging of HCV by using machine learning

Understanding the stages of hepatitis C is essential for guiding decisions about clinical care, risk assessment, and treatment. 80% of other people with the disease do not feel symptoms, but the infection remains [13,14]. With early detection and treatment, the chance of developing a chronic hepatitis C infection can be reduced, and the disease can be prevented from progressing. The dataset contains information on four distinct stages of the hepatitis C virus (HCV): cirrhosis, portal fibrosis without septa, portal fibrosis with a few septa, and portal fibrosis with several septa. The sample distribution for every category is displayed in figure 1.

The purpose of the study is to use artificial neural networks (ANNs) to estimate various stages of hepatitis C disease. When tested by humans, such tests use the error correction back-propagation algorithm by artificial neural networks until they learn on their own at last. Due to the advice given by some professionals, some datums concerning 1385 HCV patients were subjected to preprocessing and refining. Several phases of disease severity have been identified from these data.



Figure 1: Shows the stages of HCV and the sample distribution.

For diagnosing hepatitis several research have proposed different frameworks with their techniques ranging from decision trees, neural networks, extreme learning machines, strong box-cox transformation, rough sets to extreme learning machines. Several problems were encountered by many individuals, such as fitting too well during training or not well enough after, using traditional machine learning approaches; however, some achieved very good accuracies [15]. Through the application of machine learning algorithms, AI helps to stage hepatitis C by accurately determining the level of liver fibrosis as well as other disease conditions. There are several advantages to using AI-based techniques in this case

- **Enhanced Accuracy:** When compared to traditional methods for staging hepatitis C, the complexity of clinical data that is analyzed by AI models helps make it more reliable and precise. In addition, A.I. systems can utilize numerous inputs so as to improve diagnoses of such stages as fibrosis of the liver.

- **Non-Invasive Assessment:** Artificial intelligence (AI) techniques, such as machine learning algorithms used to non-invasive imaging modalities including ultrasound, magnetic resonance elastography (MRE), transient elastography (Fibro Scan), and serum biomarkers, enable non-invasive assessment of liver fibrosis. Consequently, less intrusive liver surgery is needed.
- **Early Detection and Monitoring:** AI systems can detect subtle changes in the course of liver fibrosis over time, allowing for the early detection of the disease's progression and timely intervention. AI-based techniques continuously monitor treatment response and disease activity, enabling customized care strategies for hepatitis C patients.
- **Risk stratification:** AI algorithms are able to classify hepatitis C patients based on their risk of acquiring cirrhosis and hepatocellular carcinoma (HCC), two diseases that can exacerbate the illness. Healthcare practitioners may be able to enhance patient outcomes if high-risk patients are identified and antiviral therapy or liver cancer screening is prioritized for treatment.

The AI selection plays an important role in staging hepatitis C because it helps define the disease stages with precision without the need for invasive procedures like liver biopsy reducing both patient identification at early-stage risks and individualized treatment plan creation. Thus, its use by medical practitioners results in better results of patients and higher performance in healthcare delivery on Hepatitis C.

Forecasting the failure of the treatment programs using artificial intelligence

Regression analysis is a challenge because the factors that contribute to treatment failure vary among individuals and have complex interconnections. Moreover, conventional statistical methods are limited to handling linear data. In contrast, machine-learning (ML) methods can handle both linear and nonlinear data, uncover hidden relationships between variables, and process massive volumes of data [16]. Popular supervised machine learning techniques include decision trees (DT), random forests (RF), artificial neural networks (ANN), and Extreme Gradient Boosting (XGBoost) [17] [18]. Thus, by combining "automatic learning" with multidimensional data, AI offers a novel method for comprehending diseases. The quality of healthcare diagnosis can now be improved and used as a decision-support tool thanks to advancements in AI. Machine learning (ML) is a preferable solution for managing large amounts of nonlinear data since it is scalable and versatile. The AI model predicted that patients with decompensation-prone liver cirrhosis characteristics—higher AST, bilirubin, and FIB-4 index values; lower albumin and platelet levels—would have a lesser likelihood of achieving SVR. Patients with active HCC are at risk for treatment failure due to their increased AFP levels and decreased BMI (i.e., weight loss). Furthermore, patients with high viral loads had more difficulty getting rid of the virus than those with low baseline viral levels. Multivariate regression analysis results are consistent with AI findings. Clinicians are aware of the optimal range of significant variables that lead to SVR. Before starting DAA medication, physicians can identify high-risk individuals and risk indicators with the help of the AI prediction model. A gradient boosting framework supports XG Boost, a supervised machine learning approach. The ensemble technique integrates multiple models to get more accurate projections. Gradient boosting is an ensemble approach that creates new models and adds them sequentially until further optimization is not feasible. This allows errors in the original models to be corrected. Because it uses a gradient descent method to reduce loss when constructing new models, this procedure is known as gradient boosting [38]. Furthermore, XG Boost is capable of performing classification and regression tasks. When XG Boost is compared to the other algorithms in our analysis, it does in fact show exceptional prediction abilities. According to a meta-analysis, patients with active HCC had a substantially lower SVR rate (73.1%) than either inactive HCC patients (92.6%) or non-HCC patients (93.3%) [19].

Challenges and limitations

Algorithm bias

The problem with many AI technologies that essentially ought to be the technology that is supposed to be more advanced than us humans but we have come to learn otherwise is that they are largely highly biased on their training-sets. Such model training biases frquently result in skewed outcomes and distorted predictions hence an unfair masking of some undesirable aspects; such as racial disparities or continuous illness monitoring disparities depending on demographic groups for instance, in sickness screening; meaning that this bias can affect a given group of people disproportionately than another group with which they belong even though they may be from different races…"All practitioners need to do is select…which are heterogeneous enough not just including but also excluding various other Enumerator: Racial groups were mostly excluded from this kind of error analysis because they were predominantly occuring in the same training data. This is not enough since understanding these biased systems requires more than just ensuring diversity [20].

These models frequently exhibit two biases: (1) spectrum bias and (2) overfitting. When patients' generated data were not a representative sample of the target population during the models' internal validation and training, spectrum bias results. Conversely, overfitting denotes a model's propensity to be tailored specifically for the training set of data [21]. As a result, the model's performance is overstated for the training dataset but drastically worse for new datasets. CNNs are especially prone to overfitting since they are widely utilized in hepatology and gastroenterology [23].

In order to prevent the introduction or escalation of health care inequities, the American Medical Association has lately recognized the necessity of identifying and addressing bias in data while testing or deploying AI/ML-based software. The main difficulty, then, lies in creating AI/ML-based software that can identify biases in the data while also unlocking the inherent value concealed within.

Ethical considerations

The utilization of AI in healthcare leads to some tough ethical and regulatory challenges with some people expressing worries about patient confidentiality, permission and responsibility while others remain unmoved. Therefore, for both the patients' wellbeing and correct application of AI techniques, there is need to consider both moral precepts such as beneficence and non-maleficence plus laws like the GDPR or HIPAA [49].

AI has the potential to become a third party in the doctor-patient relationship and undermine trust. First, the idea that data exchanged with third parties for AI model building may cause patients to become less forthcoming and withhold information from their physicians [22]. Second, a crucial aspect of a doctor's clinical practice is empathy, which AI/ML-based models are unable to replicate.

It can be difficult to strike a balance between maintaining a high standard of care and preventing invasions of privacy. With the development of computer vision, for instance, surveillance could be used to identify any departures from the best bedside procedures, such patient mobilization and hand cleanliness, which exposes patients to identifying risks. Data reduction, or gathering the least amount of data necessary, is one technique that could help with these issues [24].

Integration with clinical workflow

In clinical practice, effective use of AI-based screening and prediction technologies calls for their seamless integration into existing healthcare workflows as well as electronic health record systems. Decision support technology needs to be accessible to clinicians with user-friendly interfaces so that they can improve their workflows and decision-making processes but not disrupt them. Using AI and ML-based tools to predict and screen hepatitis C in clinical workflow is a process that must be organized systematically so as to fit within already existing healthcare systems. For it to guarantee utmost utility, effectiveness and satisfaction among healthcare providers, it is imperative to consider a number of important factors:

- **User-Centric Design**: Any AI solution for the requirements, and doctor's workflows, has to be based on the user-centered design principles when satisfying them in healthcare. When we involve physicians at the beginning stage rather than at the end stage, it makes sure that these are designed in simple language which makes it easy for them to understand; hence they are also following usual clinical procedures [48].
- **Continuous Assessment and Improvement**: It is important that monitoring and evaluation of Artificial Intelligence (AI) technologies in clinical practice are carried out on an ongoing basis for assessing the performance, discovering areas for improvement, and handling any problems or barriers that may occur. For this purpose, it is necessary to establish feedback mechanisms gathering input from both patients and health care providers so as to keep developing and enhancing AI-based screening systems over again [50].
- **Quality assurance and regulatory compliance:** In order to ensure the effective and safe use of hepatitis C screening strategies based on AI, it is necessary to comply with regulatory requirements, such as the approval of FDA or CE certification for medical devices. One of the quality assurance processes that needs to be implemented is to make sure that patients are safe, the algorithms are accurate, and data integrity is maintained in clinical application of AI throughout its entire life cycle.

Discussion and Future Work

Building on the findings and discussions presented in the paper, several avenues for future research and development in the field of AI-driven hepatitis C screening and management can be identified:

- **Validation Studies:** Running high-quality validation studies in order to examine if the AI models can really determine Hepatitis C and its prevention. They work together with healthcare facilities aiming at putting into operation and checking artificial intelligence devices used for practical purposes and finding out if in deed they are effective care delivery
- **Explainable AI Models**: Creating AI models that can be easily understood, it is possible to know how machine learning algorithms work as far as diagnosis and management of HCV is concerned. The aim is to boost medical officer's comprehension of predictions by AI-based systems hence increasing trust levels in them.
- **Integration with Clinical Workflows:** More embedded AI and ML tools should be introduced into existing clinical workflows and electronic health record systems to facilitate easy retrieval of data, increase the accuracy of diagnosis and improve care management among hepatitis C patients. It is therefore important to develop interoperability solutions which will ensure smooth access to AI technologies in standard clinical practice.
- **Personalized Treatment Strategies**: Improving AI algorithms (i.e. already-existing AI machine learning models) to facilitate tailored therapeutic (i.e. disease treatment) approaches in respect of patients suffering from hepatitis C (i.e. the enhancement of a personal approach to therapy considering individual risk profiles, progress of his/her disease and response to the treatment) is an urgent task. Particular attention should be drawn towards using predictive models for better outcome optimization as well as minimizing side effects by adjusting treatment cycles.
- **Longitudinal Data Analysis**: Utilizing AI algorithms to observe how patients respond to therapy, identifying the threats of relapse and throughout its course offering guidance for management decisions. Leveraging longitudinal data analysis for tracking how hepatic C disease advances, in its treatment outcomes or even determining what comes in the future with the patients concerned in the long term.
- **Patient-Centric Care Models**: Developing care frameworks that prioritize hepatitis C management individualized patient-centered care, shared decision-making, and patient empowerment are important. To improve patient engagement and satisfaction, it is important to ensure that the AI-based treatment plans incorporate the preferences, values, and feedback of individuals.
- **Continuous Improvement and Evaluation:** Monitoring performance metrics, collecting feedback from stakeholders, and iteratively improving algorithms by using real-world data in an AI app for hepatitis C improves a culture of continuous learning and improvement. It involves the development and maintenance of a dynamic environment for innovation and quality improvement in AI-driven healthcare solutions.

In search of these prospective research trends and recommendations in care, the aim of this paper is to contribute to advances in hepatitis C screening and management through artificial intelligence and machine learning. This will translate to improved patient-centered clinical outcomes and efficient health care delivery by targeting on the aforementioned domains in future research directions and recommendations.

Conclusion

The merging of Machine Learning (ML) with Artificial Intelligence (AI) in hepatitis C testing programs signals a new epoch in health care innovation. One such instance is within the medical health facilities where the accuracy of diagnosing hepatitis C has been enhanced by a significant margin thanks to AI algorithms as well as early detection rates. According to research findings, this can change completely how health checks are done as they may possibly identify 25% more individuals who could be infected by hepatitis C. Modernized screening models based on Artificial Intelligence (AI) could enhance sensitivity by 20% and specificity by 15% while also boosting the capacity to identify correctly those persons who are at risk of Hepatitis C infection. Improved accuracy is one of the critical advantages of utilizing machine learning (ML) together with AI in hepatitis c diagnosis. Improved patient outcomes are achievable should this happen since it helps detect the disease at an earlier stage thus leading to premature interventions by healthcare providers and individualized therapy plans. Furthermore, employing AI in hepatitis C testing might alter rate of progression within an infected person's system. Research demonstrates that screening initiatives that are driven by AI can reduce the time when someone suffers from an ailment by 30% in confirmed instances. This shows how public health outcomes can be affected too much by these initiatives. For doctors to adopt AI health procedures in clinical practice in order increase their usability, efficacy and acceptance within the profession, continual assessment of the user-friendly attributes is essential hence allowing their optimal operation within hospitals. It is vital for healthcare systems to follow regulations and provide quality assurance so that they can create AI-based screening tests using which do not only improve patient safety but also enhance the precision of algorithms without compromising on data integrity across the whole healthcare industry in a safe and cost-effective manner. The shift that has occurred in the screening of hepatitis C results from the integration of Artificial Intelligence as well as Machine Learning technologies that enhance detection of the disease, personalizing its screenings, and treatments for patients, while also promoting public health outcomes. AI-powered screening initiatives that improve the early discovery rates, accuracy, and disease evolution speeds in the context of better medical care for those susceptible to infection could truly transform the control of hepatitis C.

Acknowledgement

The authors acknowledge the support from Buch International Hospital Multan in conducting this research.

Bibliography

1. Owens DK., *et al*. "Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement". *JAMA* 323.10 (2020): 970-975.
2. Petroff D., *et al*. "Confirmation of guideline-defined hepatitis C screening strategies within the 'Check-Up35+' examination in the primary care setting". *Liver International* 43.4 (2023): 785-793.
3. Khullar V and Firpi RJ. "Hepatitis C cirrhosis: new perspectives for diagnosis and treatment". *World Journal of Hepatology* 7.14 (2015): 1843-1855.
4. Targets and Metrics. "HCV Dashboard New York, New York State Department of Health".
5. Angermueller C., *et al*. "Deep learning for computational biology". *Molecular Systems Biology* 12 (2016): 878.
6. Zhou LQ., *et al*. "Artificial intelligence in medical imaging of the liver". *World Journal Gastroenterology* 25 (2019): 672-682.
7. Chan HP., *et al*. "Deep Learning in Medical Image Analysis". *Advances in Experimental Medicine and Biology* 1213 (2020): 3-21.
8. Chevaliez S and Pawlotsky JM. "Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease". *International Journal of Medical Sciences* 3.2 (2006): 35-40.
9. Joshi SN. "Hepatitis C screening". *Ochsner Journal* 1.4 (2014): 664-668.
10. Kawka M., *et al*. "Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review". *Translational Gastroenterology and Hepatology* 7 (2022): 41.
11. Huang Q., *et al*. "Differential Diagnosis of Atypical Hepatocellular Carcinoma in Contrast-Enhanced Ultrasound Using Spatio-Temporal Diagnostic Semantics". *IEEE Journal of Biomedical and Health* (2020).
12. Chandrashekar G and Sahin F. "A survey on feature selection methods". *Computers and Electrical Engineering* 40 (2020): 16-28.
13. Taz NH., *et al*. "A comparative analysis of ensemble based machine learning techniques for diabetes identification". In: 2021 2nd International Conference on Robotics, Electrical and Signal Processing Techniques (ICREST). IEEE (2021): 1-6.
14. Do ˘gru A., *et al*. "A hybrid super ensemble learning model for the early-stage prediction of diabetes risk". *Medical and Biological Engineering and Computing* (2023): 1-13.
15. Sarma Dhiman., *et al*. "Artificial Neural Network Model for Hepatitis C Stage Detection (2020).
16. Hassabis D., *et al*. "Neuroscience-inspired artificial intelligence". *Neuron* 95 (2017): 245-258.
17. Su TH., *et al*. "Artificial intelligence in precision medicine in hepatology". *Journal of Gastroenterology and Hepatology* 36 (2021): 569-580.
18. Le Berre C., *et al*. "Application of artificial intelligence to gastroenterology and hepatology". *Gastroenterology* 158 (2020): 76-94.
19. Ji F., *et al*. "Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis". *Journal of Hepatology* 71 (2019): 473-485.
20. Crawford K and Calo R. "There is a blind spot in AI research". *Nature* 538 (2016): 311-313.
21. Yeung S., *et al*. "A computer vision system for deep learning-based detection of patient mobilization activities in the ICU". *NPJ Digital Medicine* 2 (2019): 11.
22. Park SH and Han K. "Methodologic Guide for Evaluating Clinical Performance and Effect of Artificial Intelligence Technology for Medical Diagnosis and Prediction". *Radiology* 286 (2018): 800-809.

23. Anwar SM., *et al*. "Medical Image Analysis using Convolutional Neural Networks: A Review". *Journal of Medical Systems* 42 (2018): 226.

24. Nundy S., *et al*. "Promoting Trust Between Patients and Physicians in the Era of Artificial Intelligence". *JAMA* 322 (2019): 497-498.

25. Mamdouh Farghaly H., *et al*. "Hepatitis C Virus prediction based on machine learning framework: a real-world case study in Egypt". *Knowledge and Information Systems* 65 (2023): 2595-2617.

26. Ding H., *et al*. "A framework for identification and classification of liver diseases based on machine learning algorithms". *Frontiers in Oncology* 12 (2022): 1048348.

27. Gogi Vyshali and MN Vijayalakshmi. "Review of Machine Learning Methods for the Survey on HCC Scenario and Prediction Strategy (2020): 949-951.

28. Chakraborty S., *et al*. "Advances in artificial intelligence-based diagnosis and treatment of liver diseases – Correspondence". *International Journal of Surgery* 109.10 (2023): 3234-3235.

29. Han Likai and Lili Yu. "Prediction of hepatocellular carcinoma and Edmondson-Steiner grade using an integrated work of multiple machine learning algorithms." (2023).

30. Kubota N., *et al*. "Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk". *Journal of Clinical Medicine* 9.12 (2020): 3843.

31. Han KH and Ahn SH. "How to predict HCC development in patients with chronic B viral liver disease?" *Intervirology* 48.1 (2005): 23-28.

32. Becker L., *et al*. "Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States". *Clinical Gastroenterology and Hepatology* 7.6 (2009): 696-701.

33. Abbasy., *et al*. "Predicting in-hospital mortality of cirrhotic patients hospitalized with hepatic encephalopathy". *Egyptian Liver Journal* (2022): 12.

34. Angelis I and Exarchos T. "Hepatocellular Carcinoma Detection Using Machine Learning Techniques". *Advances in Experimental Medicine and Biology* 1338 (2021): 21-29.

35. Li B., *et al*. "Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73". *Oncotarget* 8.46 (2017): 80521-80530.

36. Lee HW and Ahn SH. "Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients". *World Journal of Gastroenterology* 22.37 (2016): 8314-8321.

37. Tan Shanjuan., *et al*. "Study of Aided Diagnosis of Hepatic Carcinoma Based on Artificial Neural Network Combined with Tumor Marker Group". *Physics Procedia* 33 (2012): 172-178.

38. Abbasy M., *et al*. "Predicting in-hospital mortality of cirrhotic patients hospitalized with hepatic encephalopathy". *Egypt Liver Journal* 12 (2022): 13.

39. Zhou J., *et al*. "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)". *Liver Cancer* 12.5 (2022): 405-444.

40. World Health Organization. Global Hepatitis Report (2017).

41. Carrat F., *et al*. "Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: Aprospective cohort study". *Lancet* 393 (2019): 1453-1464.

42. Gutierrez-Osuna R. "Pattern analysis for machine olfaction: a review". *IEEE Sensors Journal* 2 (2002): 189-202.

43. Langley P. "Selection of relevant features in machine learning". In: Proceedings of the AAAI fallsymposium on relevance (1994): 245-271.

44. Breima L. "Random forests". Mach Learn 45 (2010): 5-32.

45. Le Cessie S and Van Houwelingen JC. "Ridge estimators in logistic regression". *The Journal of the Royal Statistical Society, Series C (Applied Statistics)* 41 (1992): 191-201.

46. Shu J., *et al*. "Clear cell renal cell carcinoma: CT-based radiomics features for the prediction of Fuhrman grade". *European Journal of Radiology* 109 (2018): 8-12.

47. Sperandei Sandro. "Understanding logistic regression analysis". *Biochemia Medica* 24 (2014): 12-18.

48. Cazzaniga M., *et al*. "Prediction of asymptomatic cirrhosis in chronic hepatitis C patients: accuracy of artificial neural networks compared with logistic regression models". *European Journal of Gastroenterology and Hepatology* 21.6 (2009): 681-687.

49. De Vito Dabbs., *et al*. "User-centered design and interactive health technologies for patients". *Computers, Informatics, Nursing: CIN* 27.3 (2009): 175-183.

50. Mennella C., *et al*. "Ethical and regulatory challenges of AI technologies in healthcare: A narrative review". *Heliyon* 10.4 (2024): e26297.

51. Doris Lucas and Potter Kaledio. "Continuous Monitoring and Improvement: Implement continuous monitoring of AI models to detect and correct issues in real-time". *I-Managers Journal on Artificial Intelligence and Machine Learning* (2024).